Drugs / NeoTCR P1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03970382 | Jul 2019 → Aug 2022 | cancer | PACT Pharma, Inc. | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoTCR P1 | “The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer.” NCT03970382 ↗ |
| Action | Inhibit | “simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ)” PMID 36356599 ↗ Nov 2022 |
| Modality | Cell therapy | “an autologous adoptive T cell therapy (ACT)” NCT03970382 ↗ |
| Target | TRAC | “simultaneously knockout the two endogenous TCR genes TRAC (which encodes TCRα) and TRBC (which encodes TCRβ)” PMID 36356599 ↗ Nov 2022 |